ABNOM
☆ AI Dermatology — Free Service
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
relevance score : -100.0%
ReferencesDie Q‑switched Nd:YAG‑laser is bekend vir die doeltreffende behandeling van nevus van Ota en soortgelyke toestande. Ons het 'n studie uitgevoer om te bepaal hoe goed 'n high‑fluence 1064 nm Q‑switched Nd:YAG‑laser op Mongoolse kolle in ongewone gebiede werk, sonder om die vel te verlig. Ons het 61 pasiënte met hierdie kolle bestudeer en altesaam 70 letsels geëvalueer. Die helfte van die letsels is met die laser behandel, terwyl die ander helfte onbehandeld is vir vergelyking. Ons het die resultate geëvalueer met behulp van 'n skaal en 'n toestel genaamd Mexameter® om die melanienvlakke te meet. Pasiënte is gemiddeld 14 maande in die behandelingsgroep en 18 maande in die waarnemingsgroep gevolg. Aan die einde van die studie het ons beduidende verskille gevind in die skaalwaardes en melanienvlakke tussen die behandelde en onbehandelde groepe, met die laserbehandelde groep wat beter uitkomste toon. Die high‑fluence Q‑switched Nd:YAG‑laser, sonder om velverligting te veroorsaak, was effektief en veilig vir die behandeling van hierdie ongewone Mongoolse kolle.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Ons het die doeltreffendheid en veiligheid van die gebruik van 'n spesifieke laserbehandeling vir ABNOM bestudeer en gekyk na watter faktore die resultaat kan beïnvloed. Ons het 110 pasiënte met ABNOM geëvalueer wat tussen twee en nege laserbehandelings ontvang het. Ons het gevind dat die behandeling beter gewerk het hoe langer dit toegepas is, maar dit was minder effektief by ouer pasiënte. Dit het ook beter gewerk by pasiënte met ligter vel (tipe III) en kleiner aangetaste areas (minder as 10 cm²). Wanneer melasma saam met ABNOM voorkom, het die behandeling minder effektief geword. Die kleur of die aantal geaffekteerde areas het blykbaar nie 'n verskil gemaak nie. Ongeveer 10 % van die pasiënte het donkerder kolle ná die behandeling gekry. Vroeë, veelvuldige behandelings het goeie resultate opgelewer. Ouer pasiënte met donkerder vel en donkerder kolle is meer geneig om donkerder kolle te ontwikkel na die behandeling. Vir pasiënte met ABNOM en melasma is dit beter om 'n laer‑energie laser te gebruik om te verhoed dat die melasma vererger.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Behandeling
Bleikmiddels help selde. Anders as melasma kan ABNOM met laserbehandeling verbeter word en sonder herhaling verwyder word. Laserbehandeling kan 10 tot 20 keer uitgevoer word om ABNOM te behandel.
#QS1064 laser